Glycoconjugate Vaccines Against Nosocomial Klebsiella pneumoniae Infections

Area of Science:

• Microbiology
• Immunology
• Biochemistry

Background:

• Klebsiella pneumoniae (KP) is a significant opportunistic pathogen responsible for difficult-to-treat nosocomial infections and pyogenic liver abscess (PLA) disease.
• Antibiotic resistance in KP poses a major global health threat, necessitating alternative therapeutic strategies.
• The capsular polysaccharide (CPS) of KP is a key virulence factor and a target for vaccine development.

Purpose of the Study:

• To develop novel glycoconjugate vaccines targeting Klebsiella pneumoniae K1 and K2 serotypes.
• To leverage bacteriophage-derived enzymes for the efficient production of vaccine components.
• To explore the potential of chemically conjugated oligosaccharide fragments of CPS as immunogens.

Main Methods:

• Determined the chemical structures of Klebsiella pneumoniae K1 and K2 capsular polysaccharides (CPSs).
• Utilized CPS depolymerases, specifically tail spike proteins (TSPs) from KP bacteriophages, to cleave the CPS into oligosaccharide fragments.
• Chemically conjugated the obtained oligosaccharide fragments to carrier proteins to create glycoconjugate vaccines.

Main Results:

• Successfully cleaved KP K1 and K2 CPSs using bacteriophage TSPs, yielding defined oligosaccharide fragments.
• Developed a method for chemically conjugating these oligosaccharide fragments to carrier proteins.
• Generated potential glycoconjugate vaccine candidates against Klebsiella pneumoniae.

Conclusions:

• The enzymatic cleavage of CPS by bacteriophage TSPs is an effective method for producing oligosaccharide fragments for vaccine development.
• The developed glycoconjugate vaccines show promise as a strategy to combat Klebsiella pneumoniae infections, including antibiotic-resistant strains.
• This approach offers a novel platform for developing vaccines against other polysaccharide-encapsulated bacterial pathogens.